Regen BioPharma develops new approach for boosting CAR-T cell efficiency to treat solid tumors
Regen BioPharma, Inc. has filed with the United States Patent and Trademark Office a provisional…
August 11, 2022 - 2 minutes
CAR-T Cell Therapy: Revolutionizing Oncology One Step at a Time
The idea that our immune system can be rewired to fight cancer has resulted in huge expectations and an influx of investments into the immuno-oncology field. Following the market success of immune checkpoint inhibitors, more and more attention is turning to CAR-T cell therapy, with the first CAR-T therapy, Novartis’ Kymriah, approved in 2017.
With five CAR-T therapies on the global market already and over hundreds of clinical trials currently running, the field is now booming. Read on to keep up-to-date with the evolving CAR-T cell therapy market and ongoing research.
Show More
Editor's Picks for CAR-T
- A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
- Infographic: What is CAR-T Cell Therapy & How Does it Fight Cancer?
- From Big Pharma to Startup CEO: Lessons from Kymriah Developer Gaurav Shah
- Gene-Edited T Cell Therapy Players Battle Safety Doubts
- How European Startups Have Advanced Cancer T-Cell Therapy in 2020
A Guide to Current Therapies in Immuno-Oncology
From a rich history to a growing number of therapies, the immuno-oncology landscape has changed rapidly over the last decade. In this report, we look into its past, discuss present therapeutic approaches, and provide an outlook into its future.
Go to ReportLatest CAR-T Articles
Poseida Therapeutics and Roche to focus on therapies for hematologic malignancies
Poseida Therapeutics, Inc. has entered into a broad strategic collaboration and license agreement with Roche,…
August 3, 2022 - 4 minutes
Sponsored
by WuXi Advanced Therapies
Streamlining CAR-T cell therapy manufacturing: a platform approach
Chimeric antigen receptor-T cell (CAR-T) therapy is an exciting treatment modality for blood cancers that…
July 28, 2022 - 7 minutes
Trinity, St. James’s and Legend Biotech collaborating on solid tumors
Trinity College and St. James’s Hospital Dublin (SJH) in Ireland have entered into a strategic…
June 28, 2022 - 3 minutes
Galapagos to acquire CellPoint and AboundBio to advance cell therapies
Belgian headquartered biotech Galapagos NV has acquired CellPoint and AboundBio, a move the Belgian company…
June 22, 2022 - 5 minutes
Immuneel Therapeutics raises $15M and starts patient trials for CAR-T cancer therapies
Indian biotech start-up Immuneel Therapeutics has announced it has started patient dosing in a CAR-T…
June 21, 2022 - 4 minutes
TILT Biotherapeutics raises $10M to push ahead on cancer immunotherapies
TILT Biotherapeutics (TILT), a clinical-stage Finnish biotech company developing cancer immunotherapies, has completed the first…
June 15, 2022 - 2 minutes
Japan’s five hottest biotech companies in healthcare
While historically lacking in foreign investments, Japan’s biotech scene is thriving with global investors showing…
June 15, 2022 - 6 minutes
Sponsored
by Takara Bio
Combination Therapies: Opportunities for Improved CAR-T Cell Therapy?
Chimeric antigen receptor (CAR) cell therapy offers hope where other cancer therapies have failed. However,…
March 10, 2022 - 6 minutes
Gene-Edited T Cell Therapy Players Battle Safety Doubts
Confidence in gene-edited T cell therapies from donor cells has faltered as Allogene Therapeutics paused…
October 22, 2021 - 5 minutes
A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology
CAR-T therapy has been hailed as a cure for cancer, but what really is this…
October 11, 2021 - 10 minutes
Microbiome Medicines Could Power Up CAR-T Cell Therapies
The microbiome could pave new cancer immunotherapy inroads for European biotechs, bolstered by preclinical findings…
July 28, 2021 - 5 minutes
